Liquidia Co. (NASDAQ:LQDA) Receives $24.00 Consensus Target Price from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $24.00.

A number of research firms have recently weighed in on LQDA. BTIG Research dropped their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, November 14th. Scotiabank initiated coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th.

Liquidia Trading Up 1.5 %

NASDAQ LQDA opened at $11.42 on Friday. The stock has a 50-day moving average of $10.61 and a 200-day moving average of $11.37. Liquidia has a 1-year low of $6.73 and a 1-year high of $16.99. The firm has a market cap of $966.59 million, a PE ratio of -7.01 and a beta of 0.21.

Insider Buying and Selling at Liquidia

In related news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the transaction, the chief executive officer now directly owns 812,193 shares in the company, valued at $9,023,464.23. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Caligan Partners Lp acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were acquired at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This represents a 2.19 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 21,551 shares of company stock valued at $236,021. 30.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several large investors have recently made changes to their positions in the business. Quest Partners LLC bought a new position in Liquidia during the 2nd quarter valued at approximately $27,000. Hilltop National Bank purchased a new position in shares of Liquidia in the 2nd quarter worth about $33,000. Clear Harbor Asset Management LLC bought a new position in Liquidia in the 3rd quarter worth about $100,000. Signaturefd LLC grew its position in Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after purchasing an additional 9,984 shares during the last quarter. Finally, Ballentine Partners LLC bought a new stake in Liquidia during the 3rd quarter valued at about $110,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).